KEYTRUDA 25 mg/mL concentrate for solution for infusion, Xeloda 500 mg film-coated tablets, Trodelvy 200 mg powder for concentrate for solution for infusion
GS-US-595-6184
Phase 3 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, Xeloda 500 mg film-coated tablets, Trodelvy 200 mg powder for concentrate for solution for infusion for Triple Negative Breast Cancer is a Phase 3 program (small_molecule) at Gilead Sciences International Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Gilead Sciences International Limited
- Indication
- Triple Negative Breast Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active